<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="534">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02048891</url>
  </required_header>
  <id_info>
    <org_study_id>RMB-0427-13</org_study_id>
    <nct_id>NCT02048891</nct_id>
  </id_info>
  <brief_title>Ovulation Trigger With hCG Compared to GnRH Agonist in Patients With Repeated IVF Failures</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ovulation trigger is needed in in vitro fertilization (IVF) to get mature eggs. Routinely,
      human chorionic gonadotropin (hCG) is used for that purpose given its similarity to the
      natural hormone that does this job in a natural cycle (luteinizing hormone, LH). In a
      natural cycle another hormone takes part in the process (follicle stimulating hormone, FSH).
      To induce a natural-like ovulation surge that includes LH and FSH , gonadotropin releasing
      hormone (GnRH) agonist can be given.

      The purpose of this study is to find out which approach may work better in IVF patients who
      experienced 4 IVF failures.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Fetal Heart Activity 1 Month After Oocyte Retrieval</measure>
    <time_frame>1 month after oocyte retrieval</time_frame>
    <safety_issue>No</safety_issue>
    <description>Fetal heart activity as seen by vaginal ultrsound imaging 1 month after oocyte retrieval</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients Comfort During the Luteal Phase</measure>
    <time_frame>During 2 weeks from day of oocyte retrieval</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>hCG trigger</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ovulation trigger with Ovitrelle 250 microgram, luteal support with vaginal progesterone: gel Crinone 8% daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GnRH agonist trigger</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ovulation trigger with Decapeptyl 0.2 mg, luteal support with 2 injections of 1,500 U hCG.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GnRH agonist trigger</intervention_name>
    <arm_group_label>GnRH agonist trigger</arm_group_label>
    <other_name>Oovulation trigger with Decapeptyl 0.2 mg, luteal support with 2 injections of 1,500 U hCG.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hCG trigger</intervention_name>
    <arm_group_label>hCG trigger</arm_group_label>
    <other_name>Ovulation trigger with Ovitrelle 250 microgram.</other_name>
    <other_name>Luteal support with daily progesterone gel = Crinone 8%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  IVF patients with at least 4 consecutive failures.

          -  On trigger day, no more than 10 follicles of 12 mm and up

        Exclusion Criteria:

          -  History of moderate or severe OHSS.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>IVF Unit, Rambam medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <lastchanged_date>May 20, 2015</lastchanged_date>
  <firstreceived_date>January 27, 2014</firstreceived_date>
  <firstreceived_results_date>April 29, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rambam Health Care Campus</investigator_affiliation>
    <investigator_full_name>Shahar Kol MD</investigator_full_name>
    <investigator_title>Director, IVF Unit</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Deslorelin</mesh_term>
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>hCG Trigger</title>
          <description>Ovulation trigger with Ovitrelle 250 microgram, luteal support with vaginal progesterone: gel Crinone 8% daily.
hCG trigger</description>
        </group>
        <group group_id="P2">
          <title>GnRH Agonist Trigger</title>
          <description>ovulation trigger with Decapeptyl 0.2 mg, luteal support with 2 injections of 1,500 U hCG.
GnRH agonist trigger</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>hCG Trigger</title>
          <description>Ovulation trigger with Ovitrelle 250 microgram, luteal support with vaginal progesterone: gel Crinone 8% daily.
hCG trigger</description>
        </group>
        <group group_id="B2">
          <title>GnRH Agonist Trigger</title>
          <description>ovulation trigger with Decapeptyl 0.2 mg, luteal support with 2 injections of 1,500 U hCG.
GnRH agonist trigger</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="41.5" spread="2.1"/>
                <measurement group_id="B2" value="42" spread="0"/>
                <measurement group_id="B3" value="41.7" spread="1.5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="3"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Israel</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Fetal Heart Activity 1 Month After Oocyte Retrieval</title>
        <description>Fetal heart activity as seen by vaginal ultrsound imaging 1 month after oocyte retrieval</description>
        <time_frame>1 month after oocyte retrieval</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>hCG Trigger</title>
            <description>Ovulation trigger with Ovitrelle 250 microgram, luteal support with vaginal progesterone: gel Crinone 8% daily.
hCG trigger</description>
          </group>
          <group group_id="O2">
            <title>GnRH Agonist Trigger</title>
            <description>ovulation trigger with Decapeptyl 0.2 mg, luteal support with 2 injections of 1,500 U hCG.
GnRH agonist trigger</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Fetal Heart Activity 1 Month After Oocyte Retrieval</title>
            <description>Fetal heart activity as seen by vaginal ultrsound imaging 1 month after oocyte retrieval</description>
            <units>participants with fetal heart activity</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients Comfort During the Luteal Phase</title>
        <time_frame>During 2 weeks from day of oocyte retrieval</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>hCG Trigger</title>
          <description>Ovulation trigger with Ovitrelle 250 microgram, luteal support with vaginal progesterone: gel Crinone 8% daily.
hCG trigger</description>
        </group>
        <group group_id="E2">
          <title>GnRH Agonist Trigger</title>
          <description>ovulation trigger with Decapeptyl 0.2 mg, luteal support with 2 injections of 1,500 U hCG.
GnRH agonist trigger</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Shahar Kol Director IVF Unit</name_or_title>
      <organization>Rambam health Care campus</organization>
      <phone>97247773232</phone>
      <email>skol@rambam.health.gov.il</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
